Regenicin, Inc. (RGIN) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
10 HIGH COURT LITTLE FALLS, NJ 07424 |
| State of Incorp. | WY |
| Fiscal Year End | September 30 |
| Industry (SIC) | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2023 MRQ | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 15 | 1 | 1 | 3 | 19 | 219 | |||
| Cash and cash equivalents | 15 | 1 | 1 | 3 | 19 | 219 | |||
| Other undisclosed current assets | 69 | 74 | |||||||
| Total current assets: | 15 | 1 | 1 | 3 | 88 | 293 | |||
| Noncurrent Assets | |||||||||
| Long-term investments and receivables | 67 | ||||||||
| Due from related parties | 67 | ||||||||
| Total noncurrent assets: | 67 | ||||||||
| Other undisclosed assets | 1 | 3 | 5 | 54 | |||||
| TOTAL ASSETS: | 15 | 4 | 5 | 56 | 88 | 360 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 358 | 3,888 | 3,278 | 2,696 | 2,286 | 1,399 | |||
| Interest and dividends payable | ✕ | 174 | 127 | 110 | 92 | ||||
| Employee-related liabilities | ✕ | 3,450 | 2,869 | 2,288 | 1,707 | 1,136 | |||
| Accounts payable | 103 | 89 | 138 | 68 | 281 | 263 | |||
| Accrued liabilities | 255 | 174 | 144 | 231 | 206 | ||||
| Debt | 185 | 185 | 10 | 10 | 10 | 10 | |||
| Other undisclosed current liabilities | 5,070 | 219 | 445 | 350 | 233 | 419 | |||
| Total current liabilities: | 5,613 | 4,291 | 3,733 | 3,056 | 2,529 | 1,828 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 5,613 | 4,291 | 3,733 | 3,056 | 2,529 | 1,828 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (5,597) | (3,728) | (3,728) | (3,000) | (2,441) | (1,468) | |||
| Common stock | 158 | 158 | 158 | 158 | 158 | 158 | |||
| Treasury stock, value | (4) | ||||||||
| Additional paid in capital | 10,208 | 10,208 | 10,208 | 10,178 | 10,178 | 10,178 | |||
| Accumulated other comprehensive income | 1 | 1 | |||||||
| Retained earnings (accumulated deficit) | 15,960 | (14,650) | (14,090) | (13,333) | (12,774) | (11,800) | |||
| Other undisclosed equity, attributable to parent | (31,919) | 556 | (4) | (4) | (4) | (4) | |||
| Other undisclosed equity | (560) | ||||||||
| Total equity: | (5,597) | (4,287) | (3,728) | (3,000) | (2,441) | (1,468) | |||
| TOTAL LIABILITIES AND EQUITY: | 15 | 4 | 5 | 56 | 88 | 360 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2023 TTM | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Other Operating Income) | 153 | 249 | 15 | 416 | ||||
| Gross profit: | 153 | 249 | 15 | 416 | ||||
| Operating expenses | (601) | (737) | (789) | (976) | (1,196) | |||
| Other operating income (expense), net (Other Expenses) | (38) | (22) | (19) | 13 | 310 | |||
| Other undisclosed operating income (loss) | (664) | 22 | 19 | (13) | (310) | |||
| Operating loss: | (639) | (511) | (737) | (540) | (961) | (780) | ||
| Nonoperating expense (Investment Income, Nonoperating) | (2,993) | (293) | ||||||
| Interest and debt expense | 36 | 106 | (18) | 230 | 32 | 434 | ||
| Loss from continuing operations before equity method investments, income taxes: | (603) | (405) | (755) | (310) | (3,921) | (639) | ||
| Other undisclosed loss from continuing operations before income taxes | (451) | |||||||
| Loss from continuing operations before income taxes: | (603) | (405) | (755) | (310) | (3,921) | (1,090) | ||
| Income tax expense | (2,829) | |||||||
| Loss from continuing operations: | (603) | (405) | (755) | (310) | (3,921) | (3,919) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (405) | (755) | (310) | (3,921) | (3,919) | ||
| Net loss: | (603) | (405) | (755) | (310) | (3,921) | (3,919) | ||
| Other undisclosed net income (loss) attributable to parent | (36) | 965 | 1,513 | (249) | 4,895 | 2,829 | ||
| Net income (loss) attributable to parent: | (639) | 560 | 758 | (559) | 974 | (1,090) | ||
| Other undisclosed net loss available to common stockholders, basic | (53) | (1,190) | (1,588) | |||||
| Net income (loss) available to common stockholders, diluted: | (692) | (631) | (829) | (559) | 974 | (1,090) | ||
Comprehensive Income ($ in thousands)
| 3/31/2023 TTM | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (603) | (405) | (755) | (310) | (3,921) | (3,919) | ||
| Comprehensive loss: | (603) | (405) | (755) | (310) | (3,921) | (3,919) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (248) | 2,948 | ||||||
| Comprehensive loss, net of tax, attributable to parent: | (603) | (405) | (755) | (559) | (973) | (3,919) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.